Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Calliditas Therapeutics AB Market Cap
From what 0 stock analysts predict, the share price for Calliditas Therapeutics AB (CALT) might decrease by 90.45% in the next year. This is based on a 12-month average estimation for CALT. Price targets go from $3.79688 to $3.89423. The majority of stock analysts believe CALT is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
CALT is a stock in Healthcare which has been forecasted to be worth $3.82122 as an average. On the higher end, the forecast price is $3.89423 USD by from and on the lower end CALT is forecasted to be $3.79688 by from .
These are the latest 20 analyst ratings of CALT.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Yigal Nochomovitz Citigroup | Neutral | $39 | Downgrade | May 31, 2024 |
| Maury Raycroft Jefferies | Hold | $39 | Downgrade | May 28, 2024 |
| Annabel Samimy Stifel | Hold | $40 | Downgrade | May 28, 2024 |
| Arthur He HC Wainwright & Co. | Neutral | $39 | Downgrade | May 28, 2024 |
| Arthur He HC Wainwright & Co. | Buy | $45 | Maintains | May 24, 2024 |
| Arthur He HC Wainwright & Co. | Buy | $50 | Reiterates | Feb 22, 2024 |
| Arthur He HC Wainwright & Co. | Buy | $50 | Reiterates | Nov 27, 2023 |
| Edwin Zhang HC Wainwright & Co. | Buy | $50 | Reiterates | Oct 16, 2023 |
| Edwin Zhang HC Wainwright & Co. | Buy | $50 | Reiterates | Aug 21, 2023 |
| Vamil Divan Guggenheim | Neutral | $18 | Maintains | Aug 18, 2023 |
| Edwin Zhang HC Wainwright & Co. | Buy | $60 | Initiates | Jun 20, 2023 |
| Vamil Divan Guggenheim | Neutral | $18 | Initiates | Mar 1, 2023 |
| Yigal Nochomovitz Citigroup | Buy | $79 | Maintains | Feb 24, 2023 |
| Edwin Zhang HC Wainwright & Co. | Buy | $62 | Maintains | Dec 20, 2021 |
Stifel | Buy | Initiates | Jun 30, 2020 | |
Jefferies | Buy | Initiates | Jun 30, 2020 |
When did it IPO
2020
Staff Count
222
Country
Sweden
Sector/Industry
Healthcare/Biotechnology
CEO
Market Cap
$1.10B
In 2023, CALT generated $1.21B in revenue, which was a increase of 50.32% from the previous year. This can be seen as a signal that CALT's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 16 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Calliditas Therapeutics AB will be delisted from Nasdaq Stockholm, effective September 16, 2024.
Why It Matters - Delisting from Nasdaq Stockholm signals potential financial distress for Calliditas Therapeutics, affecting stock liquidity and investor confidence, likely leading to a decline in share value.
Tue, 03 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Asahi Kasei Corporation has acquired over 90% of Calliditas Therapeutics' shares and plans to redeem the remaining shares, prompting Calliditas' Board to take corporate actions as requested.
Why It Matters - Asahi Kasei's acquisition of over 90% of Calliditas indicates a shift in control, likely leading to strategic changes, impacting Calliditas's future performance and investor returns.
Tue, 03 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Calliditas Therapeutics AB held a shareholder meeting on September 3, 2024. Further details on decisions or outcomes were not provided in the excerpt.
Why It Matters - The news highlights potential shareholder actions or corporate developments within Calliditas Therapeutics, which could influence stock performance and investor sentiment.
Tue, 13 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Calliditas Therapeutics AB will hold its Q2 2024 earnings conference call on August 13, 2024, at 8:30 AM ET, featuring key company executives. No Q&A will follow the presentation.
Why It Matters - Calliditas' Q2 2024 earnings call indicates potential financial performance insights, impacting stock valuation and investor sentiment without an interactive Q&A for further clarity.
Tue, 13 Aug 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Calliditas Therapeutics reported Q2 2024 net sales of SEK 559.8 million, up from SEK 269.4 million in Q2 2023. TARPEYO® sales rose to SEK 493.4 million from SEK 259.2 million.
Why It Matters - Significant revenue growth for Calliditas Therapeutics, particularly from TARPEYO® sales, indicates strong market demand and potential for future profitability, impacting investor sentiment positively.
Wed, 31 Jul 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - As of July 31, 2024, Calliditas Therapeutics AB has 59,941,465 outstanding ordinary shares following the exercise of warrants from its incentive programs.
Why It Matters - The increase in outstanding shares from warrant exercises can dilute existing shareholders’ equity, potentially impacting share value and market perception of Calliditas Therapeutics.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
